Zenith Healthcare Limited (530665) Fair Value & Analysis
Other · IN · Market cap ₹247M
Fair value as of: Jul 4, 2026
From 8 valuation models · updated today
Share price −1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹2.42 – ₹4.48 · fair‑value band ₹0.9500 – ₹1.90 · the ₹3.09 price screens above the ₹1.90 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zenith Healthcare Limited (530665) currently trades at ₹3.09, while our model-based Fair Value estimate is ₹1.90 — implying the stock looks roughly 38.5% overvalued today. We read business quality at 49/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Zenith Healthcare Limited generated revenue of ₹146M at a net margin of 6.9%. Revenue grew 51.6% year over year. It earns a return on equity of 15.7%. The stock trades on a trailing P/E of 30.1. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Zenith Healthcare Limited manufactures, sells, and exports pharmaceutical formulations in India. The company offers products in the form of tablets, capsules, oral liquids, and injections in various therapeutic areas. It also engages in the contract manufacturing of various dosage forms. The company also supplies medicines to Cambodia, Myanmar, Papa New Guinea, Sri Lanka, Kenya, Nigeria, Gambia, Zambia, Namibia, Botswana, Armenia, Georgia, Uzbekistan, Paraguay, Bolivia, Venezuela, Guatemala, Barbados, Jamaica, Bahamas, Yemen, and Turkey. Zenith Healthcare Limited was founded in 1994 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Zenith Healthcare Limited reported revenue of ₹105M in FY2026 versus ₹224M in FY2022, a compound −17.2%/yr. Reported net income was ₹51.0K in FY2026, compounding −64.2%/yr from FY2022.
Is 530665 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Zenith Healthcare Limited (530665) undervalued?
What is the fair value of 530665?
What is the quality score of 530665?
What is the revenue of Zenith Healthcare Limited (530665)?
What is the net profit margin of 530665?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.